salvage ct041 cldn18.2-specific car t-cell therapy for patients with advanced gi malignancies
Published 2 years ago • 306 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
0:34
expanding indications for a cldn18.2-specific car t-cell therapy in gi cancers
-
0:55
future directions for cldn18.2-specific car t-cell therapy in gi cancers
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
1:59
car-t therapy for previously treated solid tumors in the digestive tract
-
6:48
car-t cell therapy against caludin 18.2 for gi cancers
-
1:49
the challenges in implementing car-t cell therapy for the treatment of solid tumors
-
1:04
what does the future hold for car-t cells in gastric cancers?
-
1:02
the use of car-t cell products in a real-world setting
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
34:53
engineered t cell with cars and tcrs for hematologic malignancy
-
2:23
car t-cells: refining cll therapy with clinical trials
-
1:17
cart19-be-01 trial: next-generation car t-cell therapy for cd19 r/r leukemia and lymphoma
-
2:30
car t-cell therapy at fox chase
-
1:20
reengineering chimeric antigen receptor t cells for targeted therapy of autoimmunity
-
2:20
a child's guide side effects of car t-cell therapy
-
2:01
advances in cd22/cd19 car-t sequential therapy
-
2:12
fully human anti-cd19 and cd22 bispecific tandem car-t